Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine.
For patients with acute myeloid leukemia refractory to intensive chemotherapy prognosis is very poor and treatment options are limited. 5-Azacytidine, a demethylating drug, is effective in the treatment of myelodysplastic syndromes when administered at a low-dose, subcutaneously. We report a case of a patient with AML refractory to induction chemotherapy as well as to two high-dose salvage regimens. The patient achieved CR through monotherapy with low-dose azacytidine.
Kuendgen
A
A
Department of Hematology, Oncology, Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, D-40225 Düsseldorf, Germany. kuendgen@med.uni-duesseldorf.de
Gräf
T
T
Zohren
F
F
Hildebrandt
B
B
Hünerlitürkoglu
A
A
Gattermann
N
N
Haas
R
R
Kobbe
G
G
D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001374:Azacitidine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D007951:Leukemia, Myeloid / Q000175:diagnosis* / Q000188:drug therapy*; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D012074:Remission Induction
D001374:Azacitidine